Website maintenance took place on Thursday 30 April 2026. If you experience any issues, please contact us.
Notice for beremagene geperpavec (Global Pharma Consulting Pty Ltd)
Active ingredients
beremagene geperpavec
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
suspension for topical application
Indication
For the treatment of dystrophic epidermolysis bullosa
Therapeutic area
Dermatology